MK0507A Phase III Double-Blind, Comparative Study
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma
Intervention: dorzolamide hydrochloride (+) timolol maleate (Drug); Comparator: timolol maleate (Drug); Comparator: dorzolamide hydrochloride (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1. 0% / timolol 0. 5%)
with 1) timolol 0. 5% and with 2) concomitant therapy with dorzolamide 1. 0% / timolol 0. 5% in
patients with glaucoma and ocular hypertension.
Clinical Details
Official title: Multicenter, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Intraocular pressure reductionSafety profile
Secondary outcome: Intraocular pressure reduction rateOutflow pressure reduction rate
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with glaucoma and ocular hypertension
Exclusion Criteria:
- History of ocular surgery within 3 months.
- Administration contradiction to timolol and dorzolamide.
Locations and Contacts
Additional Information
Starting date: March 2007
Last updated: March 5, 2008
|
